USD icon

ProShares Ultra Semiconductors

38.71 USD
-0.94
2.37%
At close Apr 28, 4:00 PM EDT
Pre-market
38.35
-0.36
0.93%
1 day
-2.37%
5 days
22.93%
1 month
-5.19%
3 months
-32.68%
6 months
-43.61%
Year to date
-42.70%
1 year
-15.07%
5 years
558.33%
10 years
1,992.43%
0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,550% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 2

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

147% more call options, than puts

Call options by funds: $23M | Put options by funds: $9.28M

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

46% more capital invested

Capital invested by funds: $56.5M [Q3] → $82.7M (+$26.2M) [Q4]

30% more funds holding

Funds holding: 40 [Q3] → 52 (+12) [Q4]

2.23% more ownership

Funds ownership: 4.84% [Q3] → 7.08% (+2.23%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for USD.

Financial journalist opinion

Neutral
ETF Trends
1 week ago
Top Performing Leveraged/Inverse ETFs: 04/13/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 04/13/2025
Neutral
Accesswire
4 weeks ago
Idaho Strategic Reports Record Operating and Financial Performance for 2024
Annual Revenue Increased 88.66%, While Annual Net Income Increased 663.27% Ended 2024 With Cash and Investments in US Treasury Notes Totaling $16,091,024 Achieved Nine Consecutive Quarters of GAAP Profitability COEUR D'ALENE, ID / ACCESS Newswire / March 31, 2025 / Idaho Strategic Resources, Inc. (NYSE American:IDR) ("IDR", "Idaho Strategic" or the "Company") today announced its consolidated operating and financial results for the year ending December 31, 2024. IDR achieved record annual gold production and financial performance during 2024.
Idaho Strategic Reports Record Operating and Financial Performance for 2024
Neutral
Accesswire
1 month ago
Pantheon Resources PLC Announces Unaudited Interim Results
Interim Results (unaudited) for the six months ended 31 December 2024 LONDON, UNITED KINGDOM / ACCESS Newswire / March 24, 2025 / Pantheon Resources plc (AIM:PANR) ("Pantheon" or "the Company"), the oil and gas company with a 100% working interest in the Kodiak and Ahpun projects, collectively spanning 258,000 contiguous acres in close proximity to pipeline and transportation infrastructure on Alaska's North Slope, announces its interim results for the six months ended 31 December 2024 (the "Period"), together with operational highlights for the half year and the period beyond. Highlights Operational and Corporate Appointed accomplished energy executive Max Easley as Chief Executive Officer, succeeding Jay Cheatham Drilled the Megrez-1 test well as an appraisal of the Ahpun East project area - Megrez-1 exceeded pre-drill expectations with total of 1,340 ft of interpreted net pay.
Pantheon Resources PLC Announces Unaudited Interim Results
Positive
Seeking Alpha
1 month ago
Why Chinese Equities Are Outperforming Wall Street
Has the AI trade moved to China? Why Chinese chipmakers may soon change the semiconductor space.
Why Chinese Equities Are Outperforming Wall Street
Positive
Seeking Alpha
1 month ago
3 Semiconductor Innovations To Watch In 2025
As the semiconductor industry moves to smaller scales, it must overcome several technical challenges. In 2025, we expect three key developments to make headlines: Gate-All-Around transistor designs, Backside Power Delivery, and an increased focus on semiconductor assembly and packaging.
3 Semiconductor Innovations To Watch In 2025
Neutral
Seeking Alpha
2 months ago
Undercovered ETFs: Growth, Income, TIPS, Poland +
The 'Undercovered' Dozen series highlights 12 lesser-known ETFs offering potential investment opportunities for investors. Kurtis Hemmerling shares a bearish take on iShares Russell Top 200 Growth ETF due to poor factor implementation, despite its strong historical performance. Goldman Sachs Nasdaq-100 Core Premium Income ETF is given a buy from Jonathan Weber for income-oriented investors, combining a 10% dividend yield with tech exposure.
Undercovered ETFs: Growth, Income, TIPS, Poland +
Negative
Seeking Alpha
2 months ago
Are Critical Minerals Trump Card In U.S.-China Chip Showdown?
On Dec. 3, 2024, China's Ministry of Commerce implemented export bans on key semiconductor materials, including gallium and germanium, to the US. US-China tensions centered on semiconductors and critical minerals are apt to continue rising as each government deploys the levers at its disposal, including restrictions on the upstream supply of materials key to the chip sector.
Are Critical Minerals Trump Card In U.S.-China Chip Showdown?
Neutral
Accesswire
2 months ago
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
This Press Release updates numerical list in reference section Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 13, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the previous University of Manitoba research has now been validated, proving that RuvidarTM is safe and effective in the inactivation of Herpes Simplex Virus, Type 1 ("HSV-1") in an animal model.
CORRECTING AND REPLACING: Theralase(R) Demonstrates Effective Treatment of Herpes
Neutral
Accesswire
2 months ago
Theralase(R) Demonstrates Effective Treatment of Herpes
Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCESS Newswire / February 12, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the previous University of Manitoba research has now been validated, proving that RuvidarTM is safe and effective in the inactivation of Herpes Simplex Virus, Type 1 ("HSV-1") in an animal model.
Theralase(R) Demonstrates Effective Treatment of Herpes
Neutral
Seeking Alpha
2 months ago
USD: Capitalizing On AI And Semiconductor Growth With 2x Leverage
USD seeks 2x daily returns of the Dow Jones U.S. Semiconductor Index, with Nvidia making up over 40% of the ETF. The growing demand for semiconductors, driven by AI and everyday electronics, supports a bullish outlook for USD. The cyclical nature of semiconductors and geopolitical risks could lead to significant price swings and deviations from the 2x return target.
USD: Capitalizing On AI And Semiconductor Growth With 2x Leverage
Charts implemented using Lightweight Charts™